W. Born, Management of Crohn's disease in adults, Am J Gastroenterol, vol.104, pp.465-83, 2009.

W. Zinsmeister, A. Sandborn, and W. , The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study, Gastroenterology, vol.121, pp.255-60, 2001.

. Jr, National Cooperative Crohn's Disease Study: results of drug treatment, Gastroenterology, vol.77, pp.847-69, 1979.

W. Tremaine, American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease, Gastroenterology, vol.130, pp.940-87, 2006.

L. Sutherland, Azathioprine and 6-mer- captopurine in Crohn disease: a metaanalysis, Ann Intern Med, vol.123, pp.132-174, 1995.

N. Branche, J. Sandborn, W. Colombel, and J. , Efficacy and safety of tumor necrosis antagonists in Crohn's disease: a metaanalysis of placebo-controlled trials, Clin Gastroenterol Hepatol, vol.6, issue.13, pp.644-53, 2008.

F. Kern and . Jr, Development of a Crohn's disease activity index, Gastroenterology, vol.70, pp.439-483, 1976.

G. Gerig, M. Goodman, and R. , A controlled double blind study of azathioprine in the management of Crohn's disease, Gut, vol.37, pp.674-682, 1995.

M. Lesser and F. Daum, A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease, Gastroenterology Present DH, Korelitz BI, vol.119, pp.895-902, 2000.

. Infliximab, Azathioprine, or Both for Crohn's Disease n engl j med 362, 2010.

J. Glass, D. Sachar, and B. Pasternack, Treatment of Crohn's disease with 6-mercapto- purine: a long-term, randomized, doubleblind study, N Engl J Med, vol.302, pp.981-988, 1980.

A. Black, H. Mcleod, and R. Powrie, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine, Gastroenterology Ann Intern Med, vol.118129, pp.705-13716, 1998.

G. Lichtenstein and R. Diamond, Wag- 26. ner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials, Am J Gastroenterol Aliment Pharmacol Ther, vol.10330, pp.1428-35210, 2008.

C. , D. Haens, and G. , Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial, Gastroenterology, vol.134, pp.1861-1869, 2008.

H. Sandborn and W. , Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease, Am J Gastroenterol, vol.104, pp.2524-2557, 2009.

P. Dinndorf and M. Avigan, Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease, J Pediatr Gastroenterol Nutr, vol.44, pp.265-272, 2007.